Patient characteristics prior to start therapy with GO
. | . | . | . | Blood count at molecular relapse . | . | . | . | . | . | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Patient no. . | Age/sex . | FAB . | BCR type . | Hb, g/dL . | WBC, × 109/L . | Platelets, × 109/L . | Disease status, molecular relapse . | Duration of molecular remission prior to GO, mos. . | Previous therapies . | ||
| 1 | 68/M | M3 | Bcr1 | 16.1 | 5.5 | 190 | 1st | 25 | AIDA 0493 | ||
| 2 | 69/M | M3 | Bcr3 | 15.2 | 7.5 | 127 | 1st | 8 | AIDA 0493 | ||
| 3 | 21/M | M3 | Bcr1 | 14.9 | 6.6 | 222 | 1st | 4 | AIDA 0493 | ||
| 4 | 42/M | M3 | Bcr1 | 16.1 | 4.6 | 193 | 1st | 42 | AIDA 0493 | ||
| 5 | 68/M | M3 | Bcr1 | 13.0 | 5.3 | 95 | 1st | 10 | AIDA 0493 | ||
| 6 | 34/M | M3 | Bcr1 | 13.0 | 7.7 | 208 | 1st | 60 | AIDA 0493 | ||
| 7 | 48/M | M3 | Bcr2 | 14.5 | 5.7 | 189 | 1st | 13 | AIDA 0493 | ||
| 8* | 50/F | M3 | Bcr1 | 13.4 | 4.4 | 180 | 1st | 7 | ATRA + IDA | ||
| 9 | 52/F | M3 | Bcr3 | 15.0 | 4.0 | 157 | 2nd | 15 | AIDA/MITOX + ARA-C | ||
| 10 | 17/M | M3 | Bcr3 | 13.8 | 4.5 | 221 | 2nd | 21 | AIDA/MITOX + ARA-C | ||
| 11 | 42/M | M3v | Bcr3 | 12.2 | 3.7 | 188 | 2nd | 10 | AIDA/MITOX + ARA-C/alloSCT | ||
| 12 | 71/M | M3 | Bcr3 | 15.3 | 5.1 | 185 | 2nd | 9 | AIDA/ATO | ||
| 13 | 23/M | M3v | Bcr3 | 12.5 | 3.1 | 127 | 2nd | 20 | AIDA/ATO/alloSCT | ||
| 14 | 77/M | M3v | Bcr3 | 12.2 | 5.6 | 141 | 3rd | 10 | AIDA/MITOX + ARA-C/ATRA | ||
| 15 | 76/M | M3 | Bcr1 | 11.3 | 3.0 | 101 | 3rd | 18 | AIDA/MITOX + ARA-C/ATO | ||
| 16 | 75/M | M3 | Bcr3 | 16.1 | 4.2 | 118 | 4th | 20 | ATRA + MITOX + ARA-C/ATO | ||
. | . | . | . | Blood count at molecular relapse . | . | . | . | . | . | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Patient no. . | Age/sex . | FAB . | BCR type . | Hb, g/dL . | WBC, × 109/L . | Platelets, × 109/L . | Disease status, molecular relapse . | Duration of molecular remission prior to GO, mos. . | Previous therapies . | ||
| 1 | 68/M | M3 | Bcr1 | 16.1 | 5.5 | 190 | 1st | 25 | AIDA 0493 | ||
| 2 | 69/M | M3 | Bcr3 | 15.2 | 7.5 | 127 | 1st | 8 | AIDA 0493 | ||
| 3 | 21/M | M3 | Bcr1 | 14.9 | 6.6 | 222 | 1st | 4 | AIDA 0493 | ||
| 4 | 42/M | M3 | Bcr1 | 16.1 | 4.6 | 193 | 1st | 42 | AIDA 0493 | ||
| 5 | 68/M | M3 | Bcr1 | 13.0 | 5.3 | 95 | 1st | 10 | AIDA 0493 | ||
| 6 | 34/M | M3 | Bcr1 | 13.0 | 7.7 | 208 | 1st | 60 | AIDA 0493 | ||
| 7 | 48/M | M3 | Bcr2 | 14.5 | 5.7 | 189 | 1st | 13 | AIDA 0493 | ||
| 8* | 50/F | M3 | Bcr1 | 13.4 | 4.4 | 180 | 1st | 7 | ATRA + IDA | ||
| 9 | 52/F | M3 | Bcr3 | 15.0 | 4.0 | 157 | 2nd | 15 | AIDA/MITOX + ARA-C | ||
| 10 | 17/M | M3 | Bcr3 | 13.8 | 4.5 | 221 | 2nd | 21 | AIDA/MITOX + ARA-C | ||
| 11 | 42/M | M3v | Bcr3 | 12.2 | 3.7 | 188 | 2nd | 10 | AIDA/MITOX + ARA-C/alloSCT | ||
| 12 | 71/M | M3 | Bcr3 | 15.3 | 5.1 | 185 | 2nd | 9 | AIDA/ATO | ||
| 13 | 23/M | M3v | Bcr3 | 12.5 | 3.1 | 127 | 2nd | 20 | AIDA/ATO/alloSCT | ||
| 14 | 77/M | M3v | Bcr3 | 12.2 | 5.6 | 141 | 3rd | 10 | AIDA/MITOX + ARA-C/ATRA | ||
| 15 | 76/M | M3 | Bcr1 | 11.3 | 3.0 | 101 | 3rd | 18 | AIDA/MITOX + ARA-C/ATO | ||
| 16 | 75/M | M3 | Bcr3 | 16.1 | 4.2 | 118 | 4th | 20 | ATRA + MITOX + ARA-C/ATO | ||
FAB indicates French-American-British; BCR, breakpoint cluster region; Hb, hemoglobin; WBC, white blood cell; AIDA 0493 (ATRA plus idarubicin); IDA, idarubicin; MITOX, mitoxantrone; ARA-C, arabinosyl cytosine; and alloSCT, allogeneic stem cell transplantation.
This patient had received GO prior to first molecular relapse during front-line consolidation.